Open AccessEffect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes
Author(s) -
Steven E. Nissen,
Taro Tsunoda,
E. Murat Tuzcu,
Paul Schoenhagen,
Christopher B. Cooper,
Muhammad Yasin,
Gregory M. Eaton,
Michael A. Lauer,
W. Scott Sheldon,
Cindy L. Grines,
Stephen W. Halpern,
Tim Crowe,
James C. Blankenship,
Richard A. Kerensky
Publication year - 2003
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.290.17.2292
Subject(s) - medicine , atheroma , intravascular ultrasound , placebo , cardiology , confidence interval , coronary atherosclerosis , apolipoprotein b , cholesterol , coronary artery disease , pathology , alternative medicine
Although low levels of high-density lipoprotein cholesterol (HDL-C) increase risk for coronary disease, no data exist regarding potential benefits of administration of HDL-C or an HDL mimetic. ApoA-I Milano is a variant of apolipoprotein A-I identified in individuals in rural Italy who exhibit very low levels of HDL. Infusion of recombinant ApoA-I Milano-phospholipid complexes produces rapid regression of atherosclerosis in animal models.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom